Neshanic Station, NJ, United States of America

Meng Pan

USPTO Granted Patents = 7 

 

Average Co-Inventor Count = 4.8

ph-index = 2

Forward Citations = 9(Granted Patents)


Location History:

  • Branchburg, NJ (US) (2011)
  • Neshanic Station, NJ (US) (2008 - 2013)

Company Filing History:


Years Active: 2008-2013

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: Inventor Meng Pan: Innovating Cannabinoid Modulators

Introduction

Meng Pan, an accomplished inventor based in Neshanic Station, New Jersey, has made significant contributions to the field of cannabinoid research. With an impressive portfolio of seven patents, he has dedicated his work to developing innovative compounds that can potentially improve health outcomes related to various disorders.

Latest Patents

Among his latest innovations are the hexahydro-cycloheptapyrazole cannabinoid modulators. This invention is directed towards a novel hexahydro-cycloheptapyrazole cannabinoid modulator compound, specifically a compound of formula (I). The primary focus of this invention is to provide a method for treating, ameliorating, or preventing conditions related to cannabinoid receptor-mediated syndromes, disorders, or diseases.

Career Highlights

Meng Pan works at Janssen Pharmaceutica NV, a globally recognized pharmaceutical company. His expertise in cannabinoid modulation has placed him at the forefront of pharmaceutical innovations aimed at enhancing therapeutic options for patients suffering from diverse conditions.

Collaborations

Throughout his career, Pan has collaborated with esteemed colleagues such as Michael P. Wachter and Fina Liotta. These partnerships have been instrumental in driving forward the research and development of cannabinoid-based therapies.

Conclusion

In summary, Meng Pan stands out as a pioneering inventor in the realm of cannabinoid research. With his extensive patent portfolio and collaborative spirit, he continues to push the boundaries of innovation in the pharmaceutical industry, aiming to offer new hope for those affected by cannabinoid receptor-related disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…